Abstract
The prior phase III, randomized CONFIRM trial compared the previously approved dose of fulvestrant (250 mg every 28 days) versus a higher dose (500 mg every 28 days plus an additional 500 mg on day 14 of the first month) in postmenopausal women with locally advanced or metastatic estrogen-receptor–positive breast cancer that recurred or progressed …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
